|
|
sticholysin || |
|
Vaxjo ID |
326 |
|
Vaccine Adjuvant Name |
sticholysin || |
|
Description |
Sticholysin (St) II is a pore-forming protein from the Caribbean Sea anemone Stichodactyla helianthus. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Structure |
Pore-forming protein. |
|
Preparation |
Encapsulated with OVA into liposomes (Lp/OVA/StII). |
|
Function |
As a way to avoid this hurdle, sticholysin (St) II, a pore-forming protein from the Caribbean Sea anemone Stichodactyla helianthus, was encapsulated with OVA into liposomes (Lp/OVA/StII) to assess their efficacy to induce a CTL response. |
| References |
Laborde et al., 2017: Laborde RJ, Sanchez-Ferras O, Luzardo MC, Cruz-Leal Y, Fernández A, Mesa C, Oliver L, Canet L, Abreu-Butin L, Nogueira CV, Tejuca M, Pazos F, Ãlvarez C, Alonso ME, Longo-Maugéri IM, Starnbach MN, Higgins DE, Fernández LE, Lanio ME. Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response. Journal of immunology (Baltimore, Md. : 1950). 2017; 198(7); 2772-2784. [PubMed: 28258198].
|
|
